MEMORANDUM

From: Chief Scientist,

Regional Director,

EURO

Date: 30 May 2025

Science Division

Our ref:

Attention:

To:

Your ref:

H9-87-34

Through:

Originator:

Dr Pascale Allotey,

Director, SRH

Subject: SPECIAL PROGRAMME OF RESEARCH,

> DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION (HRP), POLICY AND COORDINATION COMMITTEE (PCC),

APPLICATIONS FOR CATEGORY (3)

MEMBERSHIP

The Policy and Coordination Committee (PCC) is the governing body of the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP). Attached for your information is a copy of the Memorandum on the Administrative Structure of the Special Programme (HRP MOU), which defines the structure, functions and mode of operation of HRP, including the membership of PCC. Also attached, for your information, is the current list of PCC members in 2025.

The membership of PCC is described in paragraph 2.2 of the MOU, and includes as category 3, two members elected by PCC for three-year terms from interested remaining Cooperating Parties. The term of office of one member in category 3 will come to an end on 31 December 2026. It will therefore be necessary for an election to take place at the Thirtyninth meeting of PCC, which will take place in Geneva and on 22 and 23 April 2026.

In accordance with the terms of the HRP MOU, all governments in the European Region, except those that may be listed as a category 1 or category 2 member, are eligible for election under category 3. The term of office of the newly-elected member will run from 1 January 2027 to 31 December 2029.

In accordance with paragraph 2.2 of the HRP MOU, PCC members may be re-elected.

ENCLS: (2)

Director, Division of Country Health Policies and Systems (CPS), EURO cc:

I would be grateful if you would take the necessary action within your Region to solicit applications for category 3 membership for among the above-mentioned eligible governments by 21 February 2026, which is 60 days before the start of the Thirty-ninth meeting of PCC and the deadline for the receipt of applications.

Applications should be sent directly to Dr Pascale Allotey, Director of the Special Programme (alloteyp@who.int **and** murcottj@who.int), outlining the motivation for applying, specifically noting work on family planning, research and development and in human reproduction and fertility regulation, as demonstrated by national policies and programmes.

If candidatures are received by the WHO Representatives or by the Regional Office, the date of receipt must immediately be stamped on the incoming correspondence, and be forwarded to HRP by e-mail (murcottj@who.int) to avoid postal delays.

Once the member is elected at the April 2026 meeting, an invitation will be extended to the government/organization concerned to nominate their representatives for the three-year term of office on PCC.

Thanking you for your timely action in regard of the above.

Dr Jeremy Farrar Chief Scientist